“Maryland, Paris Medicen to Partner on Disease Research and Translational Medicine” Video Interview at BIO International Convention 2012

http://marylandbiocenter.org/Pages/Homepage.aspx

http://medicen.org/

http://www.choosemaryland.org/pressroom/Pages/MD,ParisMedicentoPartneronDiseaseResearchTranslationalMedicine.aspx

SNNLive had the pleasure of speaking with Dr. Judith Britz, Executive Director of Maryland Biotechnology Center and Francois Chevillard, CEO of the Medicen Paris Region to announce the two organizations’ Memorandum of Understanding at the BIO International Convention 2012 in Boston, MA. The Maryland Biotechnology Center is an organization within the Maryland Department of Business and Economic Development (DBED) that consolidates and coordinates a host of state, university and private sector initiatives to better showcase and support biotechnology innovation and entrepreneurship in Maryland. The Medicen Paris Region facilitates the transfer of innovation to industry, the market and patients in human healthcare sectors.

Both Dr. Britz and Mr. Chevillard were both very excited about the opportunities that lie ahead: “state of maryland has 500 companies in biotechnology, but we recognize that we are not an island, and we live in a world of International relationships. So, in particular, we have identified with Medicen Paris Region opportunities for our companies to work together”, Dr. Britz states. “Medicen Paris Region is a bio-cluster in France with 400 biotechnological companies and academic institutions in the field of cancer, neuroscience and infectology, and we want double up our opportunities with Maryland BioTechnology Center“, Mr. Chevillard goes on to say.

For more information about the agreement, Maryland Biotechnology Center and Medicen Paris Region, please check out any of the above links. You can also follow updates about Maryland Biotechnology Center on Twitter @BioMaryland. SNNLive would like to welcome Dr. Judith Britz and Francois Chevillard and offer our congratulations and much success in the future. As Mr. Chevillard concluded, “we are here to serve humanity and help the patient find new treatment for their illness.” We wish you all the best of luck.